Dopamine, Prefrontal Cortex and Working Memory Functioning in Schizophrenia

E. M. Meisenzahl; J. Scheuerecker; G. J. S. Schmitt; H. J. Möller

doi:10.1055/s-2007-992132

Pharmacopsychiatry, Table of Contents

Pharmacopsychiatry 2007; 40: S62-S72
DOI: 10.1055/s-2007-992132

Original Paper

Dopamine, Prefrontal Cortex and Working Memory Functioning in Schizophrenia

E. M. Meisenzahl¹ , J. Scheuerecker¹ , G. J. S. Schmitt¹ , H. J. Möller¹

¹Department of Psychiatry, Ludwig-Maximilians-University of Munich, Munich, Germany

Abstract

Proposing working memory disturbances as one of the core symptoms of cognitive deficits in schizophrenia the authors summarize and discuss the dependency on prefrontal cortex functioning and working memory performance. On the basis of a strong association of prefrontal functioning and the dopaminergic system the authors refer to schizophrenia as an illustrative example. Altered dopamine function and associated working memory performance are discussed with regard to effects of psychopharmacological treatment to modulate cognitive processes.

Full Text

References

1 Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M. et al . Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry. 1998; 155 761-767
2 Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS. et al . Increased baseline occupancy of D₂ receptors by dopamine in schizophrenia. Proc Natl Acad Sci USA. 2000; 97 ((14)) 8104-8109
3 Abler B, Erk S, Walter H. Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebocontrolled fMRI study. Psychopharmacology. 2007; 191 ((3)) 823-833
4 Addington J, Addington D. Cognitive functioning in first-episode schizophrenia. J Psychiatry Neurosci. 2002; 27 ((3)) 188-192
5 Andreasen N. Negative symptoms in schizophrenia. definition and reliability. Arch Gen Psychiatry. 1982; 39 ((7)) 784-788
6 Andreasen NC, Flashman L, Flaum M, Arndt S, Swayze V, O'Leary DS. et al . Regional brain abnormalities in schizophrenia measured with magnetic resonance imaging. JAMA. 1994; 272 ((22)) 1763-1769
7 Andreasen NC, Nopoulos P, O'Leary DS, Miller DD, Wassink T, Flaum M. Defining the phenotype of schizophrenia: cognitive dysmetria and its neural mechanisms. Biol Psychiatry.. 1999; 46 ((7)) 908-920
8 Andreasen NC, Nasrallah HA, Dunn VD. et al . Structural abnormalities in the frontal system in schizophrenia: A magnetic resonance imaging study. Arch Gen Psychiatry. 1986; 43 136-144
9 Andreasen NC, Paradiso S, O'Leary DS. Cognitive dysmetria as an integrative theory of schizophrenia: A dysfunction in cortical-cerebellar circuitry?. Schizophr Bull. 1998; 24 203-218
10 Baddeley A. Wm. Oxford University Press 1986
11 Baddeley A. Working Memory. Science. 1992; 255 556-559
12 Baker K, Baldeweg T, Sivagnanasundaram S, Scambler P, Skuse D. COMT Val108/158 Met modifies mismatch negativity and cognitive function in 22q11 deletion syndrome. Biol Psychiatry. 2005; 58 ((1)) 23-31
13 Bannon MJ, Michelhaugh SK, Wang J, Sacchetti P. The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders. Eur Neuropsychopharmacol. 2001; 11 449-455
14 Barch D, Carter C, Braver T, Sabb F, MacDonald AR, Noll D. et al . Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry. 2001; 58 ((3)) 280-288
15 Bender W, Albus M, Möller HJ, Tretter F. Towards systemic theories in biological psychiatry. Pharmacopsychiatry. 2006; 39 ((1)) 4-9
16 Bertolino A, Blasi G, Caforio G, Latorre V, DeCandia M, Rubino V. et al . Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biol Psychiatry. 2004; 56 ((3)) 190-197
17 Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X. et al . Neurocognitive correlates of the COMT Val (158)Met polymorphism in chronic schizophrenia. Biol Psychiatry. 2002; 52 ((7)) 701-707
18 Braver TS, Cohen JD. Dopamine, cognitive control, and schizophrenia: the gating model. Prog Brain Res. 1999; 121 327-349
19 Broadbent D. Perception and communication. Pergamon: Oxford 1985
20 Bruder GE, Keilp JG, Xu H, Shikhman M, Schori E, Gorman J. et al . Catechol-O-methyltransferase (COMT) genotypes and working memory: associations with differing cognitive operations. Biol Psychiatry. 2005; 58 ((11)) 901-907
21 Callicott JH, Ramsey NF, Tallent K, Bertolino A, Knable MB, Coppola R, Goldberg T, Gelderen P van, Mattay VS, Frank JA, Moonen CT, Weinberger DR. Functional magnetic resonance imaging brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacol. 1998; 18 ((3)) 186-196
22 Callicott J, Mattay V, Verchinski B, Marenco S, Egan M, Weinberger D. Complexity of prefrontal cortical dysfunction in schizophrenia: more than up or down. Am J Psychiatry. 2003; 160 ((12)) 2209-2215
23 Callicott JH, Bertolino A, Mattay VS, Langheim F, Duyn J, Coppola R. et al . Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex. 2000; 10 ((11)) 1078-1092
24 Cannon TD, Zorrilla LE, Shtasel D, Gur RE, Gur RC, Marco EJ. et al . Neuropsychological functioning in siblings discordant for schizophrenia and healthy volunteers. Arch Gen Psychiatry.. 1994; 51 ((8)) 651-661
25 Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry.. 2006; 39 ((1)) 10-14
26 Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1988; 1 179-186
27 Chafee MV, Goldman-Rakic PS. Inactivation of parietal and prefrontal cortex reveals interdependence of neural activity during memory-guided saccades. J Neurophysiol. 2000; 83 ((3)) 1550-1566
28 Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci. 1983; 3 ((8)) 1607-1619
29 Christensen J, Holcomb J, Garver DL. State-related changes in cerebral white matter may underlie psychosis exacerbation. Psychiatry Res. 2004; 130 ((1)) 71-78
30 Cohen JD, Braver TS, Brown JW. Computational perspectives on dopamine function in prefrontal cortex. Curr Opin Neurobiol. 2002; 12 ((2)) 223-229
31 Cohen JD, Dunbar K, MacLelland JL. On the control of automatic processes: A parallel distributed processing model of the Stroop effect. Psychol Rev. 1990; 97 ((3)) 332-361
32 Cohen JD, Servan-Schreiber D. Context, cortex and dopamine: A connectionist approach to behavior and biology in schizophrenia. Psychol Rev. 1992; 99 45-77
33 Daniel DG, Weinberger DR, Jones DW, Zigun JR, Coppola R, Handel S. et al . The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci. 1991; 11 1907-1917
34 Dao-Castellana MH, Paillere-Martinot ML, Hantraye P, Attar-Levy D, Remy P, Crouzel C. et al . Presynaptic dopaminergic function in the striatum of schizophrenic patients. Schizophr Res. 1997; 23 ((2)) 167-174
35 Davis JM, Andriukaitis S. The natural course of schizophrenia and effective maintenance drug treatment. J Clin Psychopharmacol. 1986; 6 2-10
36 Dayan P, Williams J. Putting the coputation back into computational modeling. Pharmacopsychiatry. 2006; 39 ((1)) 50-51
37 Deco G. A dynamical model of event-related FMRI signals in prefrontal cortex: predictions for schizophrenia. Pharmacopsychiatry. 2006; 39 ((1)) 65-67
38 Diamond A, Goldman-Rakic PS. Comparison of human infants and rhesus monkeys on Piaget's AB task: evidence for dependence on dorsolateral prefrontal cortex. Exp Brain Res. 1989; 74 ((1)) 24-40
39 Diamond A, Prevor MB, Callender G, Druin DP. Prefrontal cortex cognitive deficits in children treated early and continuously for PKU. Monogr Soc Res Child Dev. 1997; 62 ((4)) 1-208
40 Doran AR, Boronow J, Weinberger DR, Wolkowitz OM, Breier A, Pickar D. Structural brain pathology in schizophrenia revisited. Prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology.. 1987; 1 ((1)) 25-32
41 Dreher JC, Guigon E, Burnod, Y. A model of prefrontal cortex dopaminergic modulation during the delayed alternation task. J Cogn Neurosci. 2002; 14 ((6)) 853-865
42 Fahim C, Stip E, Mancini-Marie A, Gendron A, Mensour B, Beauregard M. Differential hemodynamic brain activity in schizophrenia patients with blunted affect during quetiapine treatment. J Clin Psychophamacology. 2005; 25 ((4)) 367-371
043 Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. et al . Positron emission tomographic analysis of central D₁ and D₂ dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry. 1992; 49 ((7)) 538-544
44 Farde L, Wiesel F-A, Hall H, Halldin C, Stone-Elander S, Sedvall G. No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry. 1987; 44 671
45 Farde L, Wiesel F-A, Stone-Elander S, Halldin C, Nordström A-L, Hall H. et al . D² dopamine receptors in neuroleptic-naive schizophrenic patients. A positron Emission Tomography study with raclopride. Arch Gen Psychiatry. 1990; 47 213-219
46 Fitzgerald PB, Kapur S, Remington G, Roy P, Zipursky RB. Predicting haloperidol occupancy of central dopamine D₂ receptors from plasma levels. Psychopharmacology. 2000; 149 ((1)) 1-5
47 Floresco SB, Magyar O. Mesocortical dopamine modulation of executive functions: beyond working memory. Psychopharmacology. 2006; 188 ((4)) 567-585
48 Frank MJ, Loughry B, O'Reilly RC. Interactions between frontal cortex and basal ganglia in working memory: a computational model. Cogn Affect Behav Neurosci. 2001; 1 ((2)) 137-160
49 Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF. et al . Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry. 2002; 54 ((1)) 40-48
50 Garver DL, Holcomb JA, Christensen JD. Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biol Psychiatry. 2005; 58 ((1)) 62-66
51 Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of casecontrol and family-based studies. Am J Psychiatry. 2003; 160 ((3)) 469-476
52 Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS. et al . Executive subprocesses in working memory-relationship to catechol-Omethyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry. 2003; 60 889
53 Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D. et al . Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery. Am J Psychiatry. 1993; 150 ((9)) 1355-1362
54 Goldman-Rakic P. Handbook of Physiology: the Nervous System (vol 5) Circuitry of primate prefrontal cortex and regulation of behaviour by representational memory. American Physiological Society. 1987; 373-417
55 Good MF, Kiss I, Buiteman C, Woodley H, Ruui Q, Whitehorn D, Kopala L. Improvement in cognitive functioning in patients with first- episode psychosis during treatment with quetiapine: an interim analysis. Brit Jour of Psych. 2002; 43 45-49
56 Gorelova N, Seamans JK, Yang CR. Mechanisms of dopamine activation of fastspiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol. 2002; 88 ((6)) 3150-3166
57 Gourovitch M, Goldberg T. Schizophrenia: A neuropsychological perspective, chapter cognitive deficits in schizophrenia: Attention, executive functions, memory and language processing. Wiley:Chichester 1996: 71-86
58 Green M. Schizophrenia from a neurocognitive perspective. Allyn and Bacon: Boston 1998
59 Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr Bull. 2000; 26 ((1)) 119-136
60 Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am J Psychiatry. 1996; 153 ((3)) 321-330
61 Gruber AJ, Dayan P, Gutkin BS, Solla SA. Dopamine modulation in the basal ganglia locks the gate to working memory. J Comput Neurosci. 2006; 20 ((2)) 153-166
62 Gur RE, Cowell PE, Latshaw A, Turetsky BI, Grossman RI, Arnold SE. et al . Reduced dorsal and orbital prefrontal gray matter volumes in schizophrenia. Arch Gen Psychiatry. 2000; 57 ((8)) 761-768
63 Heiden U an der. Schizophrenia as a dynamical disease. Pharmacopsychiatry. 2006; 39 ((1)) 36-42
64 Hazy TE, Frank MJ, O'Reilly RC. Banishing the homunculus: making wm work. Neuroscience. 2006; 139 ((1)) 105-118
65 Hegarty JD, Baldessarini RJ, Tohen M, Waternaux C, Oepen G. One hundred years of schizophrenia: a meta-analysis of the outcome literature. Am J Psychiatry. 1994; 151 1409-1416
66 Hoffman RE, McGlashan TH. Using a speech perception neural network computer simulation to contrast neuroanatomic versus neuromodulatory models of auditory hallucinations. Pharmacopsychiatry. 2006; 39 ((1)) 54-64
67 Honea R, Crow TJ, Passingham D, Mackay CE. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry. 2005; 162 ((12)) 2233-2245
68 Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci. 1999; 96 ((23)) 13432-13437
69 Hsiao MC, Lin KJ, Liu CY, Tzen KY, Yen TC. Dopamine transporter change in drug-naive schizophrenia: an imaging study with [^99mTc]-TRODAT-1. Schizophr Res. 2003; 65 39-46
70 Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TR, Joyce EM. Executive function in first-episode schizophrenia. Psychol Med. 1998; 28 ((2)) 463-73
71 Jahn T, Cohen R, Mai N, Ehrensperger M, Marquardt C, Nitsche N. et al . Untersuchung der fein- und grobmotorischen Dysdiadochokinese schizophrener Patienten: Methodenentwicklung und erste Ergebnisse einer computergestützten Mikroanalyse. Z Klin Psychol. 1995; 24 300-315
72 Johnstone EC. Disabilities and circumstances of schizophrenic patients: A follow-up study. Br J Psychiatry. 1995; 159 5-46
73 Jones HM, Brammer MJ, OŽToole M, Taylor T, Ohlsen RI, Brown RG. et al . Cortical effects of quetiapine in first-episode schizophrenia: a preliminary functional magnetic resonance imaging study. Biol Psychiatry. 2004; 56 938-942
74 Juckel G, Schlagenhauf F, Koslowski M, Filonov D, Wüstenberg T, Villringer A. et al . Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology. 2006a; 187 ((2)) 222-228
75 Juckel G, Schlagenhauf F, Koslowski M, Wüstenberg T, Villringer A, Knutson B. et al . Dysfunction of ventral striatal reward prediction in schizophrenia. Neuroimage. 2006b; 29 ((2)) 409-416
76 Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D₂ receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosi. 2000; 25 ((2)) 161-166
77 Knutson B, Adams CM, Fong GW, Hommer D. Anticipation of increasing monetary reward selectively recruits nucleus accumbens. J Neurosci. 2001; 21 ((16)) RC159
78 Koob GF, Sanna PP, Bloom FE. Neuroscience of addiction. Neuron. 1998; 21 ((3)) 467-476
79 Koob GF, Moal M Le. Drug abuse: hedonic homeostatic dysregulation. Science. 1997; 278 ((5335)) 52-58
80 Laakso A, Vilkman H, Alakare B, Haaparanta M, Bergman J, Solin O. et al . Striatal Dopamine Transporter Binding in Neuroleptic-Naive Patients with Schizophrenia Studied with Positron Emission Tomography. Am J Psychiatry. 2000; 157 269-271
81 Laruelle M, Abi-Dargham A, Dyck CH van, Gil R, D'Souza CD, Erdos J. et al . Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996; 93 9235-9240
82 Laruelle M, Abi-Dargham A, Gil R, Kegeles L, Innis R. Increased dopamine transmission in schizophrenia: relationship to illness phases. Biol Psychiatry. 1999; 46 ((1)) 56-72
83 Laruelle M. Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab. 2000; 20 ((3)) 423-451
84 Laruelle M, Abi-Dargham A, Dyck C van, Gil R, DŽSouza DC, Krystal J. et al . Dopamine and serotonin transporters in patients with schizophrenia: An imaging study with [¹²³I] ß-CIT. Biol Psychiatry. 2000; 47 371-379
85 Lavalaye J, Linszen DH, Booij J, Dingemans PMAJ, Reneman L, Habraken JBA. et al . Dopamine transporter density in young patients with schizophrenia assessed with FP-CIT SPECT. Schizophrenia Res. 2001; 47 59-67
86 Laywer G, Nyman H, Agartz I, Arnborg S, Jönsson EG, Sedvall GC. et al . Morphological correlates to cognitive dysfunction in schizophrenia as studied with Bayesian regression. BMC Psychiatry. 2006; 6 31
87 Lewis DA. Development of the prefrontal cortex during adolescence: Insights into vulnerable neural circuits in schizophrenia. Neuropsychopharmacology. 1997; 16 358-398
88 Lidow MS, Koh PO, Arnsten AFT. D1 dopamine receptors in the mouse prefrontal cortex: Immunocytochemical and cognitive neuropharmacological analyses. Synapse. 2003; 47 ((2)) 101-108
89 Lieberman JA. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry. 1999; 46 ((6)) 729-739
90 Lieberman J, Bogerts B, Degreef G, Ashtari M, Lantos G, Alvir J. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am J Psychiatry. 1992; 149 784-794
91 Lieberman J, Kane J, Woerner M, Alvir J, Borenstein M, Novacenko H. Prediction of relapse in schizophrenia. Clin Neuropharmacol. 1990; 13 434-435
92 Lieberman JA, Sheitman BB, Kinon BJ. Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. Neuropsychopharmacology. 1997; 17 205-229
93 Loebel AD, Lieberman JA, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR. Duration of psychosis and outcome in first-episode schizophrenia. Am J Psychiatry. 1992; 149 1183-1188
94 Lynd-Balta E, Haber SN. The organization of midbrain projections to the striatum in the primate: ensorimotor-related striatum versus ventral striatum. Neuroscience. 1994a; 59 ((3)) 625-640
95 Lynd-Balta E, Haber SN. The organization of midbrain projections to the ventral striatum in the primate. Neuroscience. 1994b; 59 ((3)) 609-623
96 Maher BA, Manschreck TC, Woods BT, Yurgelun-Todd DA, Tsuang MT. Frontal brain volume and context effects in short-term recall in schizophrenia. Biol Psychiatry. 1995; 37 ((3)) 144-150
97 Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry. 2002; 159 ((4)) 652-654
98 Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E. et al . Schizophrenic subjects show aberrant fmri activation of dorsolateral prefrontal cortex and basal ganglia during wm performance. Biol Psychiatry. 2000; 48 ((2)) 99-00
99 Mathalon DH, Sullivan EV, Lim KO, Pfefferbaum A. Progressive brain volume changes and the clinical course of schizophrenia in men: a longitudinal magnetic resonance imaging study. Arch Gen Psychiatry. 2001; 58 ((2)) 148-157
100 Matsumoto M, Weickert CS, Beltaifa S, Kolachana B, Chen JS, Hyde TM. et al . Catechol O-methyltransferase (COMT) mRNA expression in the dorsolateral prefrontal cortex of patients with schizophrenia. Neuropsychopharmacology. 2003; 28 1521
101 Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF. et al . Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA. 2003; 100 ((10)) 6186-6191
102 MacClure RK, Phillips I, Jazayerli R, Barnett A, Coppola R, Weinberger DR. Regional change in brain morphometry in schizophrenia associated with antipsychotic treatment. Psychiatry Res. 2006; 148 ((2-3)) 121-132
103 Meisenzahl E, Scheuerecker J, Zipse M, Ufer S, Wiesmann M, Frodl T. et al . Effects of treatment with the atypical neuroleptic quetiapine on wm function: an functional mri follow-up investigation. Europ Arch Psychiatry Clin Neurosci. 2006; 256 ((8)) 522-531
104 Meltzer HY, Matsubara S, Lee JC. The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. Psychopharmacol Bull. 1989; 25 ((3)) 390-392
105 Menon RS. Imaging function in the working brain with fmri. Current Opinion in Neurobiology. 2001; 11 ((5)) 630-636
106 Möller H. Can negative symptoms of schizophrenia be partially or totally controlled by antipsychotics?. Eur Neuropsychopharmacol. 1999; 9 ((5)) 135-136
107 Norman KA, O'Reilly RC. Modeling hippocampal and neocortical contributions to recognition memory: A complementary learning systems approach. Psychol Rev. 2003; 110 611-646
108 Nuechterlein KH, Dawson ME. Information processing and attentional functioning in the developmental course of schizophrenic disorders. Schizophr Bull. 1984; 10 ((2)) 160-203
109 Perlstein W, Dixit N, Carter C, Noll D, Cohen J. Prefrontal cortex dysfunction mediates deficits in wm and prepotent responding in schizophrenia. Biol Psychiatry. 2003; 53 ((1)) 25-38
110 Perry W, Light GA, Davis H, Braff DL. Schizophrenia patients demonstrate a dissociation on declarative and non-decclarative memory test. Schizophr Res. 2000; 46 167-174
111 Pessoa L, Gutierrez E, Bandettini P, Ungerleider L. Neural correlates of visual wm: fMRI amplitude predicts task performance. Neuron. 2002; 35 ((5)) 975-987
112 Petrides M. The role of the mid-dorsolateral prefrontal cortex in wm. Exp Brain Res. 2000; 133 44-54
113 Pilowsky LS, Costa DC, Ell PJ, Verhoeff NP, Murray RM, Kervin RW. Dopamine D₂ receptor occupancy in vivo and response to the new antipsychotic risperidone. Br J Psychiatry. 1994; 163 833-834 , Erratum in: Br J Psychiatry 1994 Feb; 164 270
114 Purdon SE, Malla A, Labelle A, Lit W. Neuropsychological change in patients with hizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001; 26 ((2)) 137-149
115 Raine A, Lencz T, Reynolds GP, Harrison G, Sheard C, Medley I. et al . An evaluation of structural and functional prefrontal deficits in schizophrenia: MRI and neuropsychological measures. Psychiatry Res. 1992; 45 ((2)) 123-137
116 Reeve WV, Schandler SL. Frontal lobe functioning in adolescents with attention deficit hyperactivity disorder. Adolescence. 2001; 36 749-765
117 Robinson D, Woerner M, Alvir J, Bilder R, Goldman R, Geisler S. et al . Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999; 156 544-549
118 Sakai K, Rowe JB, Passingham RE. Active maintenance in prefrontal area 46 creates distractor-resistant memory. Nat Neurosci. 2002; 5 ((5)) 479-484
119 Sawaguchi T, Matsumura M, Kubota K. Effects of dopamine antagonists on neuronal activity related to a delayed response task in monkey prefrontal cortex. J Neurophysiol. 1990; 63 ((6)) 1401-1412
120 Scheuerecker J, Ufer S, Zipse M, Wiesmann M, Brückmann H, Koutsouleris M. et al . Cerebral changes and cognitive dysfunctions in medication- free schizophrenia- an fMRI study. J Psychiatry Res. 2007;
121 Schlösser R, Wagner G, Köhler S, Sauer H. Schizophrenie als Diskonnektionssyndrom. Radiologe. 2005; 45 ((2)) 137-143
122 Schmitt GJE, Frodl T, Tatsch K, Dresel S, Möller H-J, Meisenzahl EM. Striatal dopamine transporter in drug-naive schizophrenic patients: A [^99mTc]-TRODAT-1- SPECT-Study. Europ Neuropsychopharmacology. 2000; 10 ((3)) 324
123 Schmitt GJE, Frodl T, Dresel S, Möller H-J, Meisenzahl EM. Striatal dopaminergic synapses in drug naive schizophrenics. World J Biol Psychiatry. 2001; 2 ((1)) 93
124 Schmitt GJ, Meisenzahl EM, Dresel S, Tatsch K, Rossmuller B, Frodl T. et al . Striatal dopamine D₂ receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine. J Psychopharmacol. 2002; 16 ((3)) 200-206
125 Schmitt GJE, Meisenzahl EM, Frodl T, Fougère C la, Hahn K, Möller H-J. et al . The striatal dopamine transporter in first-episode, drug-naive schizophrenic patients: Evaluation by the new SPECT-ligand [^99mTc]TRODAT-1. J Psychopharmacology. 2005; 19 488-493
126 Schmitt GJE, Frodl T, Dresel S, Fougère C la, Bottlender R, Koutsouleris N. et al . Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci. 2006; 256 115-121 , Epub 2005 Nov 15
127 Schmitt GJE, Fougère C la, Dresel S, Frodl T, Hahn K, Möller H-J. et al . Dualisotope SPECT imaging of striatal dopamine in first-episode, drug naïve schizophrenic patients. Schizophrenia Res. 2007; , (submitted)
128 Schultz W, Apicella P, Ljungberg T. Responses of monkey dopamine neurons to reward and conditioned stimuli during successive steps of learning a delayed response task. J Neurosci. 1993; 13 ((3)) 900-913
129 Schwegler H. Phenomenological modelling of some mechanisms in schizophrenia. Pharmacopsychiatry. 2006; 39 ((1)) 43-49
130 Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry. 2002; 47 ((1)) 27-38
131 Selemon LD, Rajkowska G, Goldman-Rakic PS. Abnormally high neuronal density in the chizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry. 1995; 52 ((10)) 805-818 , ; discussion 819-820.
132 Shenton ME, Dickey CC, Frumin M, MacCarley RW. A review of MRI findings in schizophrenia. Schizophr Res. 2001; 49 ((1-2)) 1-52
133 Shifman S, Bronstein M, Sternfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A. et al . A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet. 2002; 71 1296
134 Stip E, Chouinard S, Boulay LJ. On the trail of a cognitive enhancer for the treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29 ((2)) 219-232
135 Stip E, Fahim C, Mancini-Marie A, Bentaleb LA, Mensour B, Mendrek A. et al . Restoration of frontal activation during a treatment with quetiapine: a fMRI study of blunted affect in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2005; 29 ((1)) 21-26
136 Sullivan EV, Shear PK, Lim KO, Zipursky RB, Pfefferbaum A. Cognitive and motor impairments are related to gray matter volume deficits in schizophrenia. Biol Psychiatry. 1996; 39 ((4)) 234-240
137 Szymanski SR, Cannon TD, Gallacher F, Erwin RJ, Gur RE. Course of treatment response in first-episode and chronic schizophrenia. Am J Psychiatry. 1996; 153 519-525
138 Tamagaki C, Sedvall GC, Jönsson EG, Okugawa G, Hall H, Pauli S. et al . Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. Am J Psychiatry. 2005; 162 ((12)) 2315-2321
139 Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN. et al . Limbic system abnormalities identified in schizophrenia using positron emission tomography with luorodeoxyglucose and neocortical alterations with deficit syndrome. Arch Gen Psychiatry. 1992; 49 ((7)) 522-530
140 Tunbridge EM, Bannerman DM, Sharp T, Harrison PJ. Catechol-Omethyltransferase inhibition improves set shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex. J Neurosci. 2004; 24 5331
141 Tretter F, Scherer J. Schizophrenia, neurobiology and the methodology of systemic modeling. Pharmacopsychiatry. 2006; 39 ((l)) 26-35
142 Urban NN, González-Burgos G, Henze DA, Lewis DA, Barrionuevo G. Selective reduction by dopamine of excitatory synaptic inputs to pyramidal neurons in primate prefrontal cortex. J Physiol. 2002; 539 ((3)) 707-712
143 Haren NEM van, Pol HEH, Schnack HG, Cahn W, Mandl RCW, Collins DL. et al . Focal gray matter changes in schizophrenia across the course of the illness: A 5- Year Follow-Up Study. Neuropsychopharmacology. 2007; , epub ahead of print
144 Velligan DI, Bow-Thomas CC. Executive function in schizophrenia. Semin Clin Neuropsychiatry. 1999; 4 ((1)) 24-33
145 Vijayraghavan S, Wang M, Birnbaum SG, Williams GV, Arnsten AFT. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in wm. Nat Neurosci. 2007; 10 ((3)) 376-384
146 Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, Mentzel H. et al . Decreased frontal activation in schizophrenics during stimulation with the continuous performance test - a functional magnetic resonance imaging study. Europ Psychiatry. 1999; 14 ((1)) 17-1 , 24
147 Waelti P, Dickinson A, Schultz W. Dopamine responses comply with basic assumptions of formal learning theory. Nature. 2001; 412 ((6842)) 43-48
148 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK. et al . Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry. 2001; 50 ((11)) 825-844
149 Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Structural abnormalities in the cerebral cortex of chronic schizophrenic patients. Arch Gen Psychiatry.. 1979; 36 ((9)) 935-939
150 Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK. et al . Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry. 2001; 50 825
151 Weinberger DR. Schizophrenia and the frontal lobe. TINS. 1998; 11 367-370
152 Weinberger DR. From neuropathology to neurodevelopment. Lancet. 1995; 346 552-557
153 Weinberger DR, Berman K. Prefrontal function in schizophrenia: confounds and controversies. Philos Trans R Soc Lond B Biol Sci. 1996; 351 ((1346)) 1495-1503
154 Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987; 44 ((7)) 660-669
155 Williams GV, Goldman-Rakic PS. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature. 1995; 376 ((6541)) 572-575
156 Williams HJ, Glaser B, Williams NM, Norton N, Zammit S, MacGregor S. et al . No association between schizophrenia and polymorphisms in COMT in two large samples. Am J Psychiatry. 2005; 162 ((9)) 1736-1738
157 Winstanley CA, Theobald DE, Dalley JW, Cardinal RN, Robbins TW. Double dissociation between serotonergic and dopaminergic modulation of medial prefrontal 31 and orbitofrontal cortex during a test of impulsive choice. Cereb Cortex. 2006; 16 106-114
158 Winterer G, Egan MF, Kolachana BS, Goldberg TE, Coppola R, Weinberger DR. Prefrontal electrophysiologic “noise” and catechol-O-methyltransferase genotype in schizophrenia. Biol Psychiatry. 2006; 60 ((6)) 578-584
159 Winterer G, Goldman D. Genetics of human prefrontal function. Brain Res Brain Res Rev. 2003; 43 ((1)) 134-163
160 Wise RA. Addictive drugs and brain stimulation reward. Annu Rev Neurosci. 1996; 19 319-340
161 Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry.. 1992; 49 ((12)) 959-965
162 Wyatt RJ. Early intervention for schizophrenia: can the course of the illness be altered. Biol Psychiatry. 1995; 38 1-3
163 Yang YK, Yu L, Yeh LY, Chiu NT, Chen PS, Lee IH. Associated alterations of striatal dopamine D₂/D₃ receptor and transporter binding in drug-naïve patients with schizophrenia: A Dual-Isotope SPECT study. Am J Psychiatry. 2004; 161 1496-1498
164 Yang P, Chung LC, Chen CS, Chen CC. Rapid improvement in academic grades following methylphenidate treatment in attention-deficit hyperactivity disorder. Psychiatry Clin Neurosci. 2004; 58 37-41
165 Zahrt J, Taylor JR, Mathew RG, Arnsten AF. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial wm performance. J Neurosci. 1997; 17 ((21)) 8528-8535
166 Zuffante P, Leonard CM, Kuldau JM, Bauer RM, Doty EG, Bilder RM. Wm deficits in schizophrenia are not necessarily specific or associated with MRI-based estimates of area 46 volumes. Psychiatry Res. 2001; 108 ((3)) 187-209

Correspondence

E.M. Meisenzahl

Department of Psychiatry

Ludwig-Maximilians-University of Munich

Nussbaumstrasse 7

80336 Munich

Germany

Phone: +49/89/5160 57 72

Fax: +49/89/5160 34 13

Email: Eva.Meisenzahl@med.uni-muenchen.de